| San Francisco Business Times (blog) That treatment ultimately could displace Genentech Inc.’s Lucentis and Avastin or Regeneron’s Eylea for people with a blinding eye disease called wet age-related macular degeneration, or wet AMD. Data from that 40-patient trial in Australia is expected … Regeneron, Avalanche Collaborate on Eye Disease Gene TherapiesDrug Discovery & Development Regeneron, Avalanche to develop new gene therapy products in ophthalmologyPharmaceutical Business Review |
Source: Wet Macular Degeneration News From Google News